Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

King's College London at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

King's College London brings 9 presentations to ASH 2026 in New Orleans. Its research spans acute myeloid leukemia, CLL and lymphoma. It includes a first-in-class GCN2 inhibitor with venetoclax and azacitidine and measurable residual disease testing.

OrganizationASH 2026 Attendance
King's College London
London, United Kingdom
Universities & research institutes
Public research university in London with medical and life sciences faculties linked to King's Health Partners hospitals.
Symposium
Fri Dec 11
11:00am–2:00pm
Medical Crossfire®: Precision Decisions in AML – Experts Debating Frontline Therapy, Targeted Agents, and Sequencing Across Care
Frontline therapy, targeted drugs, and treatment sequencing in acute myeloid leukemia, framed around real questions from community oncologists.
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at King's College London

Tell us what you sell and we’ll find the people at King's College London most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction